HC Wainwright & Co. Reiterates Buy on ATAI Life Sciences, Maintains $15 Price Target

Benzinga · 08/30 16:01
HC Wainwright & Co. analyst Patrick Trucchio reiterates ATAI Life Sciences (NASDAQ:ATAI) with a Buy and maintains $15 price target.